MDWD$17.37
Chart
Performance
Key Stats
AI MDWD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldMediWound Ltd. operates in a promising niche of regenerative medicine but faces significant challenges with profitability and cash flow. The stock exhibits mixed signals, with some fundamental strengths tempered by operational losses and uncertain technical indicators. Investors should exercise caution and consider the high-risk nature of this biopharmaceutical company.
Thematic
MediWound's focus on novel bio-therapeutic solutions for tissue repair and regeneration aligns with growing healthcare demands. The market for advanced wound care and burn treatments is expanding, offering potential for future growth if the company can successfully commercialize its pipeline.
Fundamental
MediWound demonstrates a commitment to its core business with substantial assets, but faces significant profitability challenges. The company has consistently reported net losses, high operating expenses relative to revenue, and negative free cash flow. While the balance sheet shows a reasonable level of current assets and manageable debt, the lack of consistent profitability and positive cash generation is a major concern.
Technical
The stock is trading below key moving averages and exhibits bearish short-term momentum indicators. While the 52-week range suggests volatility, the current trend appears to be downward, with resistance overhead. Further analysis of intraday indicators reveals mixed signals, leaning towards caution.
| Factor | Score |
|---|---|
| Advanced Wound Care Market | 85 |
| Biopharmaceutical Innovation | 70 |
| Competition | 60 |
| Regulatory Hurdles | 65 |
| Intellectual Property | 75 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 25 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Earnings Per Share (EPS) | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 40 |
| Intraday Momentum (15-min) | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Innovative Bio-Pharmaceutical Focus
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing novel, non-surgical solutions for tissue repair and regeneration. Their product pipeline includes NexoBrid for eschar removal in burns, EscharEx for chronic wounds, and MW005 for non-melanoma skin cancers, indicating a strategic focus on unmet medical needs in wound care and dermatology.
Positive Short-Term Performance
The stock has shown positive performance over the last month (+5.56%) and year-to-date (+12.94%), suggesting recent investor interest and positive market sentiment.
Bearish Points (8)
Negative Earnings Per Share (EPS)
The company has consistently reported negative EPS on a trailing twelve months (TTM) basis (-$2.05) and for most recent fiscal years and quarters, indicating a lack of profitability.
Negative Price-to-Earnings (P/E) Ratio
The P/E ratio is not applicable or negative across most periods due to consistent net losses, making traditional valuation metrics unreliable and suggesting the company is not currently profitable on a per-share basis.
Calendar
August 2025
20
Next Earnings Date
H: $-0.30
A: $-0.57
L: $-0.70
H: 6.08M
A: 5.68M
L: 5.10M
Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Seasonals
Price Target
30.67 USD
The 39 analysts offering 1 year price forecasts for MDWD have a max estimate of 39.00 and a min estimate of 25.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading provider of regenerative technologies, surgical instruments, and wound care solutions, directly competing in Mediwound's core areas of advanced wound care and surgical tissue repair.
Weight: 92
Specialized in advanced wound care and surgical biologics using regenerative medicine, a direct competitor in tissue regeneration for chronic and acute wounds.
Weight: 90
Global medical technology company with a major Advanced Wound Management division, offering a wide range of wound care products including dressings, devices, and biologics.
Weight: 88
Global medical products company with a significant Advanced Wound Care segment, directly competing in various wound dressings, ostomy care, and critical care solutions.